Long-term safety of subcutaneous immunotherapy with TO-204 in Japanese patients with house dust mite-induced allergic rhinitis and allergic bronchial asthma: Multicenter, open label clinical trial

Background: To evaluate the long-term safety of subcutaneous immunotherapy with TO-204, a standardized house dust mite (HDM) allergen extracts, we conducted a multicenter, open label clinical trial. Methods: Japanese patients aged 5–65 years were eligible for the study, if they had HDM-induced aller...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Takao Fujisawa, Terufumi Shimoda, Keisuke Masuyama, Kimihiro Okubo, Kohei Honda, Mitsuhiro Okano, Toshio Katsunuma, Atsuo Urisu, Yasuto Kondo, Hiroshi Odajima, Kazuyuki Kurihara, Makoto Nagata, Masami Taniguchi, Shoichiro Taniuchi, Satoru Doi, Tomoshige Matsumoto, Shoji Hashimoto, Akihiko Tanaka, Kensuke Natsui, Nahoko Abe, Hideki Ozaki
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Elsevier 2018-07-01
Seri Bilgileri:Allergology International
Online Erişim:http://www.sciencedirect.com/science/article/pii/S132389301730165X
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller